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license (http://creativeyet, recruitment of this community to AD clinical trials is challenging.
Methods: We compared 47 African Americans and 78 whites in their willingness to enroll in a
hypothetical preclinical AD trial and examined barriers and facilitators in their decision making.
Results: African American race (OR5 0.45; 95% CI, 0.22–0.93) and score on the research attitude
questionnaire (OR 5 1.12; 95% CI, 1.04–1.22) were independently associated with willingness to
participate. African Americans rated study risks, the requirement of a study partner, study procedures,
the ratio of drug to placebo, and study location as more important factors in the decision whether to
enroll than did whites.
Discussion: These results suggest that researchers will encounter challenges in recruiting African
Americans to preclinical AD trials. Future research will be necessary to understand the optimal means
to improve recruitment of underrepresented populations.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Recruitment; Race; Minority; Prevention; Clinical trial1. Introduction
Studies show substantial variation in the incidence of Alz-
heimer’s disease (AD) dementia across racial and ethnic
groups, and African Americans may be at highest risk [1].
The incidence of AD in African Americans may be twice
as high as that of whites [1–6]. In addition, the rates of
dementia diagnosis [7–9], use of approved AD treatments
[10], and survival [11,12] are all reduced in this
community. Research is the key to understand and address
these problems. Unfortunately, few African Americans
participate in research [13,14]. Preclinical AD trials, suchthor. Tel.: 949-824-5905; Fax: 949-824-0885.
rill@uci.edu
16/j.trci.2016.09.004
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).as the anti-amyloid treatment in asymptomatic AD study
(A4 study) [15], are testing interventions in participants
before the onset of cognitive impairment or dementia. If these
studies do not include adequate representation of African
American participants, then it risks perpetuating the dispar-
ities in understanding and addressing the burden of AD in
this racial group.
Preclinical AD trials, similar to other clinical trials, face
challenges in recruitment, especially for participants from
diverse racial and ethnic populations. Strategies to enhance
minority participation in AD research are well described
[16,17], but a more thorough understanding of the barriers to
minority recruitment based on empirical data remains an
area of need. In the present study, we compared the
willingness to participate in a hypothetical preclinical ADimer’s Association. This is an open access article under the CC BY-NC-ND
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that the groups would differ in their approach to deciding
whether to participate in AD prevention trials. We examined
the influence of specific trial factors in decision making and
probed for potential incentives for each racial group by
analyzing both quantitative and qualitative data.
2. Methods
2.1. Participants
We performed a post hoc secondary analysis of an inter-
view study that examined the impact of AD biomarker disclo-
sure on AD prevention trial recruitment. The study used a
mixed-methods experimental design. One-hundred thirty-
two cognitively normal participants were randomly assigned
to one of two hypothetical AD prevention trials that either did
or did not require disclosure of the results of an amyloid posi-
tron emission tomography scan. We probed for responses of
participant willingness to enroll and factors that might affect
the decision. In the primary analysis [18], we found no differ-
ence in participant willingness to enroll, based on whether
disclosure of amyloid status was required. In addition, we
observed no interaction effects between the disclosure
requirement and any other variable, including race. In the cur-
rent analysis, we compared quantitative and qualitative data
between 78 white and 47 African American participants.
All participants were aged 65 years or more and were in-
terviewed in English. They had no previous diagnosis of de-
mentia, mild cognitive impairment, or other neurological or
psychiatric disease and no auditory or visual impairments
that prevented the conduct of the study interview. They
were recruited through a variety of mechanisms, including
community education events on AD, and multiple referral
sources (Table 1).2.2. Procedure
In a face-to-face interviewwith a research assistant, partic-








UCLA ADRC Registry, n (%) 25 (32.0) 5 (10.6)
Community talk, n (%) 14 (17.9) 16 (34.0)
Community liaison, n (%) 3 (3.8) 17 (36.2)
Community referral, n (%) 6 (7.7) 4 (8.5)
Self-referral, n (%) 7 (9.0) 0 (0)
UCLA ADRC control subjects, n (%) 7 (9.0) 0 (0)
Banner Alzheimer’s Prevention Initiative
Registry, n (%)
5 (6.4) 1 (2.1)
Caregiver support program, n (%) 3 (3.8) 1 (2.1)
Clinical referral, n (%) 2 (2.6) 1 (2.1)
Unknown, n (%) 6 (7.7) 2 (4.2)
Abbreviation: UCLA ADRC, University of California, Los Angeles
Alzheimer’s Disease Research Center.a hypotheticalADprevention clinical trial thatwas 36-months
long, double-blind, 1:1 randomized, and required visits at a
medical center every 6 months. Two versions of the ICF
were used based on experimental assignment (details can be
found in the primary article [18]). After checking for partici-
pants’ comprehension, the research assistant used structured
and open-ended questions to assess participant willingness
to enroll, aswell as which trial factors and potential incentives
affected their decision. Participants received a $25 gift card to
a national retail store for their participation.
The UCLA Institutional Review Board (IRB) approved
the study, and all participants underwent IRB-approved
informed consent.2.3. Measures2.3.1. Demographics
In addition to race, we collected participant age, gender,
ethnicity, education level, employment status, job freedom,
family history of AD, caregiver status, perceived health con-
dition, and residential distance to the medical center.
2.3.2. Likelihood to enroll in a prevention trial
The primary outcome was assessed using a single ques-
tion: “How likely would you be to enroll in the described Alz-
heimer’s disease prevention trial,” with a 6-point response
scale from “extremely unlikely” to “extremely likely.”
2.3.3. Importance of trial factors
Participants received structured questions on seven trial
factors: frequency of visits, location of visits, length of
study, requirement of a study partner, study risks, likelihood
of receiving placebo, and required procedures. Participants
used a 6-point rating scale from “extremely unimportant”
to “extremely important” to rate each factor.
2.3.4. Incentives for participation
Participants were asked an open-ended question “are there
any things that would have made you more likely to partici-
pate?” Additional structured questions asked about six incen-
tives including receiving overall study results, personal blood
test results, personal genetic test results, personal cognitive
test rests, financial compensation, and estimated personal
risk for getting AD. Participants rated each incentive on a
6-point scale ranging from making them “much less likely
to enroll” to “much more likely to enroll.”
2.3.5. Covariates
We also assessed participants’ knowledge about AD, gen-
eral attitudes toward research, perceived risk for AD, and sub-
jective cognitive performance. Knowledge about AD was
measured by the AD Knowledge Scale (ADKS) [19], a 30-
item true or false questionnaire, with higher scores represent-
ing greater knowledge. The Research Attitude Questionnaire
[20] is a 7-item, 5-point scale (score range, 7–35), for which
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research. Perceived risk for AD was measured by a 5-item,
5-point scale (score range, 5–25) [21], with higher scores re-
flecting a higher perceived risk for AD. Subjective cognitive
performance was measured by the Cognitive Change Index
[22], a 20-item, 5-point scale (score range, 20–100) that as-
sesses participants’ perceived cognitive decline, relative to
their own level of function 5 years prior. Higher scores repre-
sent greater subjective decline.2.4. Data analyses
We compared whites and African Americans on demo-
graphics and other characteristics, using unpaired t-tests
for continuous variables, chi-square tests or Fisher tests for
categorical variables, and Cochran–Armitage trend tests
for ordinal variables (e.g., self-rated health, distance to the
medical center, and job freedom).
Racial differences on willingness to enroll were exam-
ined with ordered logistic regression models. We first used
unadjusted univariate models to assess for the effects of
race and each covariate. Subsequently, using a multivariable
model, we examined the effect of race adjusting for effects
of covariates, including those covariates with P values ,.2
in univariate models. We also examined potential interaction
effects between race and the covariates. Because previousTable 2
Description of the sample
Characteristic White
n 78
Mean age, years 6 SD (range) 73.9 6 6.6 (65–89
Female gender, n (%) 51 (65.4)
Hispanic ethnicity, n (%) 5 (6.4)
Mean Education, years 6 SD (range) 16.5 6 2.7 (11–24
Retired, n (%) 61 (79.2)
Job freedom
Never, n (%) 0
Rarely, n (%) 3 (3.8)
Frequently, n (%) 13 (16.7)
Always, n (%) 62 (79.5)
ADKS score, mean 6 SD (range) 24.0 6 2.9 (18–29
RAQ score, mean 6 SD (range) 29.3 6 4.3 (7–35)
AD Caregivers, n (%) 6 (7.7)
Family History of AD, n (%) 21 (27.3)
Do you know someone with AD? 64 (82.1)
Risk for AD score, mean 6 SD (range) 16.6 6 3.8 (5–24)
Rating of overall health
Excellent, n (%) 23 (29.5)
Very good, n (%) 33 (42.3)
Good, n (%) 19 (24.4)
Fair, n (%) 3 (3.8)
Poor, n (%) 0
Distance to the medical center
0–5 miles, n (%) 40 (51.3)
5–15 miles, n (%) 22 (28.2)
15–30 miles, n (%) 10 (12.8)
.30 miles, n (%) 6 (7.7)
Abbreviations: ADKS, Alzheimer’s Disease Knowledge Scale; RAQ, Researchanalyses found no effect of the requirement of biomarker sta-
tus disclosure, this variable was not included in any model.
We examined racial differences on each trial factor and
each incentive using Cochran–Armitage trend tests. Within
each racial group, we used Friedman tests to examine for
an overall difference among the factors and the incentives
and Wilcoxon signed rank tests for post hoc pairwise com-
parisons. For open-ended responses, one investigator sepa-
rated participant interviews into separate comments and
developed preliminary themes in which comments were
included. Comments were placed on cards and three investi-
gators engaged in a consensus-forming exercise, examining
the developed themes and assigning individual comments to
those themes, blinded to participant information [23]. Partic-
ipants’ responses were coded dichotomously, indicating pre-
sent or absent, for each theme. We compared the racial
groups on the frequencies of these defined codes.
All analyses were performed in R, version 3.1.3 [24]. Re-
sults of statistical tests are reported with a significance level
of 0.05.3. Results
3.1. Participants
Participants were recruited through multiple sources
(Table 1). Community lectures served as an effectiveAfrican American P value
47
) 72.0 6 5.2 (66–83) .10
37 (78.7) .17
1 (2.1) .41







) 22.5 6 3.5 (15–29) .01
















Attitude Questionnaire; AD, Alzheimer’s disease.
Table 3
Frequency of responses to the primary outcome question, based on race
Group Extremely unlikely Very unlikely Somewhat unlikely Somewhat likely Very likely Extremely likely
White, n (%) 8 (10.3) 4 (5.1) 10 (12.8) 21 (26.9) 20 (25.6) 15 (19.2)
African American, n (%) 5 (10.6) 9 (19.1) 9 (19.1) 13 (27.7) 5 (10.6) 6 (12.8)
Total, n (%) 13 (10.4) 13 (10.4) 19 (15.2) 34 (27.2) 25 (20.0) 21 (16.8)
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rican Americans). A third of whites were recruited from the
UCLA AD Research Center potential participant registry
[25]. In contrast, a high proportion (36%) of African Ameri-
cans were recruited through the work of a community liaison
whoattended establishments such as senior centers andbeauty
salons, discussed the study, and distributed flyers.
The two racial groups were similar in age, education,
gender, employment status, perceived risk for AD, attitudes
toward research, and residential distance to the medical cen-
ter (Table 2). Similar proportions of each group knew some-
one with AD, had a family history of AD, or were caregivers
for a patient with AD. Whites had higher scores on the
ADKS (P 5 .01) and better self-rated health (P 5 .02)
than African Americans.3.2. Willingness to participate
Seventy-two percent (56 of 78) of whites and 51% (24 of
47) of African Americans reported that they were likely to
enroll in the AD prevention trial (Table 3). Univariate-
ordered logistic regression showed that African Americans
were less likely to enroll than whites (odds ratio 5 0.45;
95% confidence interval, 0.23–0.86; Table 4). In additional
univariate analyses, RAQ score (higher scores associated
with greater willingness), retirement status (not retired
more willing than retired), and perceived risk for AD
(higher perceived risk associated with greater willingness)
were significantly associated with likelihood to enroll
(P , .05; Table 4). ADKS score (P 5 .07), CognitiveTable 4




Race (white) 0.45 (0.23–0.86)*
Age 0.98 (0.94–1.04)
Education 1.06 (0.94–1.20)
RAQ score 1.12 (1.04–1.22)*
ADKS score 1.10 (0.99–1.21)
Ethnicity (Non-Latino) 0.74 (0.19–2.90)
Retirement status (Non-retired) 0.43 (0.19–0.95)*
Family history (No family history) 1.26 (0.61–2.63)
Perceived risk for AD 1.10 (1.02–1.19)*
Cognitive Change Index 1.03 (1.00–1.06)
Rating of overall health 1.15 (0.77–1.72)
Distance from the medical center 1.28 (0.91–1.81)
Abbreviations: ADKS, Alzheimer’s Disease Knowledge Scale; RAQ, Research
*P , .05.Change Index score (P 5 .05), and distance from the med-
ical center (P 5 .16) were also included in the subsequent
multivariable model.
The final multivariable model showed that, after adjust-
ing for covariates, African Americans remained signifi-
cantly less likely to enroll than whites (OR 5 0.45;
95% CI, 0.22–0.93). The only other predictor that re-
mained significant was RAQ score (OR 5 1.12; 95%
CI, 1.04–1.22), with every one point higher score associ-
ated with 12% higher likelihood to enroll. There was no
interaction effect between race and RAQ total score or be-
tween race and any of the individual RAQ items (data not
shown).3.3. Importance of trial factors
African American participants rated five of seven trial
factors as being of greater importance to the decision
whether to enroll than did whites (Fig. 1), including study
risks, the requirement of a study partner, study procedures,
ratio of drug to placebo, and study location (Cochran–Armit-
age test, P , .05). Frequency of study visits and total study
length were rated similarly by the two groups.
Within each racial group, Friedman tests showed that
participants’ ratings of importance significantly differed
among the seven trial factors (P , .0001). In both groups,
study risks and the requirement of a study partner were
rated as significantly more important than the remaining
five factors (Wilcoxon signed rank test, P , .05 for all
pairwise comparisons).Multivariable Model
P value OR (95% CI) P value
.02 0.45 (0.22–0.93)* .03
.62
.37
.006 1.12 (1.04–1.22)* .005
.07 1.06 (0.95–1.18) .26
.67
.04 0.56 (0.24–1.33) .19
.54
.02 1.08 (1.00–1.18) .07
.05 1.03 (1.00–1.06) .07
.49
.16 1.25 (0.86–1.81) .25
Attitude Questionnaire; AD, Alzheimer’s Disease.
Fig. 1. Participant ratings of the importance of trial factors in the decision whether to enroll for each racial group. * indicates P , .05 for racial differences.
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Quantitative and qualitative data showed mixed results
for potential incentives for enrollment. In response to
open-ended questions, African Americans more frequently
mentioned financial compensation (23% vs. 14%) and re-
turning of research results (19% vs. 6%) as potential incen-
tives than did whites. In structured questions that examined
six potential incentives (Fig. 2), there was no difference be-
tween African Americans and whites in the impact that
financial incentives would have on enrollment. More whites
than African Americans responded that returning cognitive
test results and returning overall study results would make
them more likely to enroll (Cochran Armitage test,
P , .05). No difference between the groups was found for
the remaining incentives.
Within each racial group, Friedman tests confirmed that
the six incentives were rated differently (P , .0001 for
whites, P , .05 for African Americans). Whites reportedthat receiving personal cognitive test results, personal risk
estimates for getting AD, personal genetic test results, and
overall study results would make them more likely to enroll
than receiving personal blood test results (Wilcoxon signed
rank test, P , .05 for all pairwise comparisons); and that
financial compensation was less effective than any other
incentive (P , .05 for all pairwise comparisons). African
Americans reported that receiving personal genetic test re-
sults would make them more likely to enroll than receiving
personal blood test results or receiving financial compensa-
tion (P , .05); and that receiving personal cognitive results
would make them more likely to enroll than receiving per-
sonal blood test results (P , .05).4. Discussion
In this study, African Americans were less likely to ex-
press a willingness to participate in AD prevention trials
Fig. 2. Participant ratings of potential incentives for participation for each racial group. * indicates P , .05 for racial differences.
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potential confounders such as knowledge about AD,
perceived risk for AD, attitudes toward research, perceived
cognitive decline, retirement status, and residential distance
from the medical center. This sample is representative of
community members that researchers will attempt to recruit
to preclinical AD trials, as they demonstrated interest and
favorable attitudes toward AD research. Therefore, our re-
sults suggest that researchers may encounter challenges in
recruiting African Americans and are in contrast to some
recent studies that suggest that African Americans are just
as likely as whites to participate in research when presented
with the opportunity [26].
African American reluctance in participating in clinical
trials and medical research is well-documented [27–30].
Past research practices with African American participants
that were self-serving and unethical have had profound influ-
ences on this community, resulting in distrust in doctors, sci-
entists, and themedical system [28,31]. The consent process,
with the goal of informing patients of study risks and
benefits, may be misinterpreted by some African
Americans as relinquishing their autonomy and as a legal
protection for doctors [28]. Our findings that African Amer-
icans more heavily weighted a variety of trial aspects,
including study risks and study procedures, in their decision
than did whites, may partly reflect these issues. Efforts toinstill trust in clinical relationships by involving African
American personnel who can explain and perform trial pro-
cedures may reduce this skepticism [32]. In this study, we
used an African American community liaison to aid in
recruitment, and this was the greatest source of African
American participants.
Both race and research attitudes were independently
associated with willingness to enroll, suggesting that
research attitudes alone cannot explain the reluctance of Af-
rican Americans to participate in AD prevention trials. In
fact, African Americans’ RAQ scores did not differ from
the scores of white participants. Others have reported diver-
gent findings. Neugroschl et al. [33] administered the RAQ
to 123 diverse attendees of community talks on cognitive ag-
ing in New York City and found that nearly half of partici-
pants had a less than positive response for the item
“participating in medical research is generally safe.” The au-
thors noted that these scores were lower than previously re-
ported means from predominantly white participants [34].
A relatively high proportion of our African American par-
ticipants were recruited through community talks. African
Americans in our study also had less factual knowledge
about AD than did whites. African Americans may have
fewer sources of information about AD than whites
[35,36] and may view memory loss as a natural and
expected part of aging, instead of as a sign of disease [37].
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trusted community members, may be a promising interven-
tion to increase minority participation in AD prevention
research. Unfortunately, our results do not explicitly instruct
which educational topics will be most effective to improving
participation rates. Nevertheless, community programs that
describe the extensive precautions in place to ensure the
voluntary nature of research and the safety of participants;
that African Americans are at increased risk for AD as a
community; and that diverse participation is needed to
reduce health care disparities represent a logical starting
point [38].
Among the limitations of this study is that it is a retro-
spective secondary analysis of a study that measured hypo-
thetical behaviors, rather than actual enrollment decisions.
The protocol was designed to examine the impact of
disclosing amyloid status on recruitment, not to examine
differences among racial groups. The questions that were
asked about trial barriers and facilitators were developed
for a general trial audience and did not address specific
racial and cultural differences. Similarly, the RAQ focuses
on general attitudes toward research, not race-specific ele-
ments. The sources of white and African American partic-
ipants differed substantially (Table 1). More white than
African American participants had previously enrolled in
longitudinal research or potential participant registries,
creating the possibility that differing levels of previous
participation [39], rather than race accounted for the
observed findings. In sub-analyses limited to those partici-
pants who were de novo recruited for this study; however,
we observed similar trends suggesting that race is associ-
ated with willingness to participate (data not shown).
Even among those enrolled in AD prevention registries, Af-
rican Americans may be less likely to endorse participation
in trials, especially those involving a drug [40]. Thus, novel
recruitment methods to not only reach diverse participants
but to overcome the barriers to their enrollment will likely
be necessary to successfully increase minority participa-
tion. These methods are needed not only for African Amer-
icans, but also for other racial and ethnic groups that are
traditionally underrepresented in AD research, such as
Latinos and Asian Americans [13,17,41].
In conclusion, our results show a significant racial differ-
ence in willingness to participate in preclinical AD trials that
is not explained by the other covariates. All of our findings
should be viewed as preliminary and will require assessment
in future research, which should seek to more fully under-
stand the barriers to minority enrollment and the optimal
means to improve recruitment of underrepresented popula-
tions. Nevertheless, differences in AD knowledge and
well-described barriers such as lack of trust suggest that
community education to inform African Americans about
AD risk and the need for equitable research participation
to overcome health disparities may be one of the keys to
improving participation rates in preclinical AD trials in
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1. Systematic review: We reviewed the literature using
traditional and Internet sources (e.g., PubMed and
Google Scholar). Many studies show that the inci-
dence of AD is disproportionately high in African
Americans. Challenges and strategies for recruiting
this racial group to AD clinical research are well
described but are infrequently based on empirical
data.
2. Interpretation: Our findings suggest that African
Americans have lower willingness to participate in
preclinical AD trials than do whites and that
improving African American participation rates
may require more than simply increasing awareness
of research opportunities within this community.
3. Future directions: Our results are based on a second-
ary analysis, rather than a study specifically designed
to examine racial differences. Future studies should
examine potential cultural factors underlying the bar-
riers to African American recruitment and should
include other minority groups traditionally underrep-
resented in AD research.
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